ABL1 and Parkinson disease: Imatinib, a c-KIT inhibitor that also inhibits Abl and PDGFRα (Iqbal and Iqbal, 2014), has been shown in preclinical models of AD to decrease levels of Aβ and pTau (Weintraub et al., 2013; Gardner et al., 2016), while it has also displayed efficacy at reducing CNS inflammation and demyelination in MS models (Azizi et al., 2014) and dopaminergic neuron death in PD models (Imam et al., 2011), indicating its potential as a therapeutic for NDDs.